| 1 |
34414850 | Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. | 2022 Jan |
1 |
| 2 |
32150297 | Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. | 2020 Aug |
1 |
| 3 |
32239921 | Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib. | 2020 May 6 |
2 |
| 4 |
30529689 | Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death. | 2019 Apr |
1 |
| 5 |
31018735 | Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. | 2019 Nov |
1 |
| 6 |
29157092 | Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. | 2018 |
1 |
| 7 |
28798402 | Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. | 2017 Aug 11 |
1 |
| 8 |
28862883 | Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. | 2017 Nov 1 |
1 |
| 9 |
28964970 | Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. | 2017 Dec |
1 |
| 10 |
26492567 | Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. | 2016 Jan |
1 |
| 11 |
27601063 | Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines. | 2016 Nov |
2 |
| 12 |
24625454 | Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. | 2014 Nov |
1 |
| 13 |
24706190 | Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. | 2014 Jun |
1 |
| 14 |
24815720 | Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. | 2014 Jul 15 |
1 |
| 15 |
25486962 | Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma. | 2014 Sep |
1 |
| 16 |
23107612 | Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. | 2013 Feb |
2 |
| 17 |
23281479 | C/EBP homologous protein (CHOP) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver. | 2013 Feb 8 |
1 |
| 18 |
23612979 | Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response. | 2013 May 31 |
2 |
| 19 |
23674497 | Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. | 2013 Jul 1 |
1 |
| 20 |
24086672 | JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. | 2013 |
1 |
| 21 |
22200786 | Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. | 2012 Apr |
3 |
| 22 |
22223138 | Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. | 2012 Jan 15 |
3 |
| 23 |
22266985 | Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. | 2012 May |
1 |
| 24 |
22479278 | A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. | 2012 Mar |
1 |
| 25 |
22535574 | A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. | 2012 Jul 15 |
2 |
| 26 |
22848091 | PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. | 2012 Oct |
2 |
| 27 |
20619923 | Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. | 2011 Mar |
1 |
| 28 |
21174067 | Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. | 2011 Mar |
3 |
| 29 |
21189393 | Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. | 2011 Feb 20 |
1 |
| 30 |
21447826 | Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. | 2011 Jun 9 |
1 |
| 31 |
21907693 | The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. | 2011 Nov |
4 |
| 32 |
20110775 | Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. | 2010 Jan |
2 |
| 33 |
20555361 | Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. | 2010 Aug |
1 |
| 34 |
20647473 | Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. | 2010 Oct 1 |
2 |
| 35 |
20665890 | Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. | 2010 Dec 1 |
3 |
| 36 |
19190324 | Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. | 2009 Feb 15 |
1 |
| 37 |
19391038 | Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. | 2009 Jun |
1 |
| 38 |
18245486 | Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. | 2008 Feb 1 |
2 |
| 39 |
18723477 | Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. | 2008 Aug |
1 |
| 40 |
17308121 | Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | 2007 Feb 15 |
1 |
| 41 |
17525289 | Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. | 2007 Oct 1 |
1 |
| 42 |
16507771 | Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. | 2006 Jun 15 |
1 |
| 43 |
16621797 | Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. | 2006 Jun 23 |
1 |